Dermata Therapeutics, Inc. (DRMA) Balance Sheet

NASDAQ: DRMAAssets, liabilities, debt and equity over 7 years.

DRMA balance sheet, 2025

December 31, 2025 · U.S. dollars

$7.9M assets = $1.6M liabilities + $6.2M equity

What it owns$7.9MCash & ST investments: $7.5M (95.7%)Cash & ST investments$7.5M · 96%Other current: $341,848 (4.3%)=How it is financed$7.9MCurrent liabilities: $1.6M (20.9%)Current liabilities$1.6M · 21%Shareholders’ equity: $6.2M (79.1%)Shareholders’ equity$6.2M · 79%

Both columns are drawn to the same scale: what DRMA owns equals what it owes plus shareholders’ equity. Hover a block for its value.

DRMA financial health

Current ratio4.79
Comfortable · current assets cover current liabilities 4.79×
Equity / assets79.1%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

DRMA balance sheet trends, 2019–2025

Dermata Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$2.1M2019$7.9M2025+25.0%/yr
Total liabilities$2.3M2019$1.6M2025−5.3%/yr
Shareholders’ equity−$210,1592019$6.2M2025—
Cash & short-term investments$2.0M2019$7.5M2025+24.8%/yr
Total debt$1.3M2019$3.5M2020+176.2%/yr
Net cash (debt)$708,0642019−$3.0M2020−$3.7M
Working capital$342,7102019$6.2M2025+$5.9M
Current ratio1.2020194.792025+3.59

Change is the average annual growth (CAGR) or the difference between the first and latest year.

DRMA assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

DRMA liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

DRMA debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

DRMA balance sheet

Dermata Therapeutics, Inc. annual balance sheet
2025202420232022202120202019
Assets
Cash & short-term investments$7.5M$3.2M$7.4M$6.2M$10.8M$530,400$2.0M
Cash & equivalents$7.5M$3.2M$7.4M$6.2M$10.8M$530,400$2.0M
Short-term investments—$3.16B—————
Receivables$0$0$8,356$12,602$0$0$0
Inventory$0$0$0$0$0$0$0
Other current assets$341,848$372,318$532,143$690,592$825,133$75,053$73,679
Total current assets$7.9M$3.5M$8.0M$6.9M$11.6M$605,453$2.1M
Property, plant & equipment (net)$0$0$0$0$0$0$322
Goodwill & intangible assets$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0
Other non-current assets$0$0$0$0$0$0$0
Total assets$7.9M$3.5M$8.0M$6.9M$11.6M$605,453$2.1M
Liabilities
Accounts payable$460,811$808,011$866,028$496,702$515,245$104,276$337,184
Short-term debt—————$3.5M$730,547
Deferred revenue——————$155,040
Total current liabilities$1.6M$2.0M$1.6M$922,634$1.5M$3.8M$1.7M
Long-term debt$0$0$0$0$0$0$553,191
Other long-term liabilities$0$1.16B$757.6M$0$0$3.6M$0
Total liabilities$1.6M$2.0M$1.6M$922,634$1.5M$3.8M$2.3M
Shareholders' equity
Common stock & paid-in capital$266$252$26$77$833$2.4M$2.4M
Retained earnings (deficit)−$73.2M−$65.7M−$53.4M−$45.6M−$36.0M−$28.1M−$24.8M
Accumulated other comprehensive income—$0———−$53.0M$0
Total shareholders' equity$6.2M$1.6M$6.4M$6.0M$10.1M−$3.2M−$210,159
Key figures
Total debt—————$3.5M$1.3M
Net cash (debt)—————−$3.0M$708,064
Working capital$6.2M$1.6M$6.4M$6.0M$10.1M−$3.2M$342,710
Tangible book value$6.2M$1.6M$6.4M$6.0M$10.1M−$3.2M−$210,159
Current ratio4.791.794.917.537.660.161.20
Quick ratio4.591.604.596.787.120.141.16
Equity / assets79.1%44.2%79.7%86.7%87.0%−524.9%−10.2%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 26, 2026); data from EODHD.

DRMA financial position

At the end of fiscal 2025 (December 31, 2025), Dermata Therapeutics had total assets of $7.9 million (up 122.5% from a year earlier), total liabilities of $1.6 million and shareholders' equity of $6.2 million. Its current ratio was 4.79. In the latest quarter (ended June 30, 2026) total assets were $5.3 million and equity $3.5 million.

Related: DRMA income statement, DRMA cash flow statement, DRMA key metrics. See the DRMA stock overview for the latest quote and news.

DRMA balance sheet FAQ

What are Dermata Therapeutics's total assets?

Dermata Therapeutics reported total assets of $7.9 million at the end of fiscal 2025 (December 31, 2025), compared with $3.5 million a year earlier.

How much cash does Dermata Therapeutics have?

Dermata Therapeutics held $7.5 million in cash and short-term investments at the end of fiscal 2025.

What is Dermata Therapeutics's book value?

Dermata Therapeutics's shareholders' equity (book value) was $6.2 million at the end of fiscal 2025.

What is Dermata Therapeutics's current ratio?

Dermata Therapeutics had current assets of $7.9 million and current liabilities of $1.6 million, a current ratio of 4.79 (it can cover its short-term obligations).

Biotechnology: balance sheet